Negoro Takaharu, Okura Hanayuki, Matsuyama Akifumi
Platform of Therapeutics for Rare Disease, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
Biores Open Access. 2017 Jun 1;6(1):63-73. doi: 10.1089/biores.2017.0013. eCollection 2017.
The induced pluripotent stem cell (iPSC) was first described more than 10 years ago and is currently used in various basic science and clinical research fields. The aim of this report is to examine the trends in research using iPSCs over the last 10 years. The 2006-2016 PubMed database was searched using the MeSH term "induced pluripotent stem cells." Only original research articles were selected, with a total of 3323 articles. These were classified according to research theme into reprogramming, differentiation protocols for specific cells and/or tissues, pathophysiological research on diseases, and discovery of new drugs, and then the trends over the years were analyzed. We also focused on 232 research publications on the pathophysiological causes of diseases and drug discovery with impact factor (IF; Thomson Reuters) of six or more. The IF of each article was summed up by year, by main target disease, and by country, and the total IF score was expressed as trends of research. The trends of research activities of reprogramming and differentiation on specific cells and/or tissues reached maxima in 2013/2014. On the other hand, research on pathophysiology and drug discovery increased continuously. The 232 articles with IF ≥6 dealt with neurological, immunological/hematological, cardiovascular, and digestive tract diseases, in that order. The majority of articles were published from the United States, followed by Japan, Germany, and United Kingdom. In conclusion, iPSCs have become a general tool for pathophysiological research on disease and drug discovery.
诱导多能干细胞(iPSC)于10多年前首次被描述,目前被应用于各种基础科学和临床研究领域。本报告的目的是研究过去10年中使用iPSC的研究趋势。使用医学主题词“诱导多能干细胞”检索了2006 - 2016年的PubMed数据库。仅选择原创研究文章,共3323篇。这些文章根据研究主题分为重编程、特定细胞和/或组织的分化方案、疾病的病理生理学研究以及新药发现,然后分析多年来的趋势。我们还重点关注了232篇关于疾病病理生理原因和药物发现的研究出版物,其影响因子(IF;汤森路透)为6或更高。按年份、主要目标疾病和国家对每篇文章的IF进行汇总,总IF得分表示为研究趋势。特定细胞和/或组织的重编程和分化研究活动趋势在2013/2014年达到峰值。另一方面,病理生理学和药物发现研究持续增加。这232篇IF≥6的文章依次涉及神经、免疫/血液、心血管和消化道疾病。大多数文章发表于美国,其次是日本、德国和英国。总之,iPSC已成为疾病病理生理学研究和药物发现的通用工具。